Randomized double-blind trial of terodiline in the treatment of urge incontinence in women

• Published in: Obstetrics and gynecology (New York. 1953) Vol. 84; no. 3; p. 386
• Main Authors: Norton, P, Karram, M, Wall, L L, Rosenzweig, B, Benson, J T, Fantl, J A
• Format: Journal Article
• Language: English
• Published: United States 01.09.1994
• Subjects: Butylamines - adverse effects; Butylamines - therapeutic use; Calcium Channel Blockers - adverse effects; Calcium Channel Blockers - therapeutic use; Double-Blind Method; Female; Humans; Middle Aged; Quality of Life; Treatment Outcome; Urinary Incontinence - drug therapy
• ISSN: 0029-7844

To evaluate the effects of terodiline in women with urge incontinence. After a 2-week run-in period, 93 women with urinary frequency and urge incontinence were randomized to either placebo or terodiline, 25 mg twice daily, in a double-blind study for 4 weeks. Symptoms were evaluated using daily frequency-volume charts to record voiding frequency, number of incontinent episodes, absorbent pad use, and quality of life. The terodiline group showed a 70% decrease in the mean (+/- standard deviation) number of incontinent episodes per week (15.8 +/- 24, decreasing to 4.9 +/- 11.9; P < .01), which persisted throughout the study period. The placebo group achieved a 9% reduction in the mean number of incontinent episodes (13.0 +/- 11.3, decreasing to 11.9 +/- 16; P < .05) only in the final week of treatment. Side effects, especially anticholinergic side effects, were more common in the terodiline group, but resulted in only one dropout. Both the treated and placebo groups improved in daytime frequency and quality-of-life indices. Terodiline is well tolerated and effective in reducing urge incontinent episodes in women.